338 related articles for article (PubMed ID: 29748315)
1. Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Pott J; Schlegel V; Teren A; Horn K; Kirsten H; Bluecher C; Kratzsch J; Loeffler M; Thiery J; Burkhardt R; Scholz M
Circ Genom Precis Med; 2018 May; 11(5):e001992. PubMed ID: 29748315
[TBL] [Abstract][Full Text] [Related]
2. Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis.
Pott J; Kheirkhah A; Gadin JR; Kleber ME; Delgado GE; Kirsten H; Forer L; Hauck SM; Burkhardt R; Scharnagl H; Loeffler M; März W; Thiery J; Gieger C; Peters A; Silveira A; Hooft FV; Kronenberg F; Scholz M
Biol Sex Differ; 2024 Mar; 15(1):26. PubMed ID: 38532495
[TBL] [Abstract][Full Text] [Related]
3. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
Chernogubova E; Strawbridge R; Mahdessian H; Mälarstig A; Krapivner S; Gigante B; Hellénius ML; de Faire U; Franco-Cereceda A; Syvänen AC; Troutt JS; Konrad RJ; Eriksson P; Hamsten A; van 't Hooft FM
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1526-34. PubMed ID: 22460556
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.
Shyamala N; Gundapaneni KK; Galimudi RK; Tupurani MA; Padala C; Puranam K; Kupsal K; Kummari R; Gantala SR; Nallamala KR; Sahu SK; Hanumanth SR
J Gene Med; 2021 Aug; 23(8):e3346. PubMed ID: 33885177
[TBL] [Abstract][Full Text] [Related]
5. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
[TBL] [Abstract][Full Text] [Related]
6. R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Mostaza JM; Lahoz C; Salinero-Fort MA; de Dios O; Castillo E; González-Alegre T; García-Iglesias F; Estirado E; Laguna F; Sabín C; López S; Cornejo V; de Burgos C; Sanchez V; Garcés C;
J Clin Lipidol; 2018; 12(4):1039-1046.e3. PubMed ID: 29773421
[TBL] [Abstract][Full Text] [Related]
7. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
Chao TH; Chen IC; Li YH; Lee PT; Tseng SY
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207972
[TBL] [Abstract][Full Text] [Related]
8. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
10. Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
Chan DC; Pang J; McQuillan BM; Hung J; Beilby JP; Barrett PH; Watts GF
Heart Lung Circ; 2016 May; 25(5):520-5. PubMed ID: 26706651
[TBL] [Abstract][Full Text] [Related]
11. Meta-GWAS on PCSK9 concentrations reveals associations of novel loci outside the PCSK9 locus in White populations.
Kheirkhah A; Schachtl-Riess JF; Lamina C; Di Maio S; Koller A; Schönherr S; Coassin S; Forer L; Sekula P; Gieger C; Peters A; Köttgen A; Eckardt KU; Kronenberg F
Atherosclerosis; 2023 Dec; 386():117384. PubMed ID: 37989062
[TBL] [Abstract][Full Text] [Related]
12. PCSK9: A novel inflammation modulator in atherosclerosis?
Tang ZH; Li TH; Peng J; Zheng J; Li TT; Liu LS; Jiang ZS; Zheng XL
J Cell Physiol; 2019 Mar; 234(3):2345-2355. PubMed ID: 30246446
[TBL] [Abstract][Full Text] [Related]
13. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
14. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study.
Bensenor I; Padilha K; Lima IR; Santos RD; Lambert G; Ramin-Mangata S; Bittencourt MS; Goulart AC; Santos IS; Mill JG; Krieger JE; Lotufo PA; Pereira AC
Front Genet; 2021; 12():728526. PubMed ID: 34659352
[TBL] [Abstract][Full Text] [Related]
16. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle-Aged Population: The STANISLAS Cohort.
Ferreira JP; Xhaard C; Lamiral Z; Borges-Canha M; Neves JS; Dandine-Roulland C; LeFloch E; Deleuze JF; Bacq-Daian D; Bozec E; Girerd N; Boivin JM; Zannad F; Rossignol P
J Am Heart Assoc; 2020 Apr; 9(7):e014758. PubMed ID: 32208829
[TBL] [Abstract][Full Text] [Related]
19. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
[TBL] [Abstract][Full Text] [Related]
20. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
